| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1996;93:1747-1754.)
© 1996 American Heart Association, Inc.
Articles |
Atrial Contractile Dysfunction After Short-term Atrial Fibrillation Is Reduced by Verapamil but Increased by BAY K8644
From the Institute for Experimental Medical Research (E.L., G.A., E.V., G.C.) and Research Forum (E.L., E.V., G.C.), University of Oslo, Ullevål Hospital, Oslo, Norway.
Correspondence to Elisabeth Leistad, MD, PhD, Institute for Experimental Medical Research, University of Oslo, Ullevål Hospital, N-0407 Oslo 4, Norway. E-mail elisabeth.leistad@ioks.uio.no.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background Reduced atrial contractility occurs after cessation of atrial fibrillation. Its mechanism is unknown, and no pharmacological treatment exists. It has been hypothesized that this atrial contractile dysfunction results from intracellular calcium overload due to rapid depolarizations during fibrillation. Accordingly, we examined the effects of drugs that reduce or increase transsarcolemmal calcium influx on postfibrillation atrial dysfunction. Furthermore, we examined whether the dysfunction could be attributed to atrial ischemia.
Methods and Results Atrial contractility after atrial fibrillation was examined in open-chest pigs paced with a constant ventricular rate after complete AV block. Atrial contractility was computed as systolic shortening of left atrial diameter divided by atrial preload. Three groups of six pigs each were subjected to two 5-minute periods of atrial fibrillation separated by 1 hour of AV pacing. Verapamil or the calcium channel agonist BAY K8644 was administered intravenously before the second fibrillation period. The degree and duration of postfibrillation atrial contractile dysfunction were reduced with verapamil but increased with BAY K8644. In a control group, parallel changes occurred after the first and second fibrillation periods. Atrial tissue content of creatine phosphate declined slightly during fibrillation, whereas the tissue content of ATP and lactate remained unchanged.
Conclusions Atrial contractile dysfunction after short-term atrial fibrillation is reduced by the calcium antagonist verapamil, which suggests that transsarcolemmal calcium influx contributed to this dysfunction. The calcium agonist BAY K8644 increased postfibrillation atrial contractile dysfunction. Atrial ischemia was not observed during fibrillation.
Key Words: fibrillation • calcium channels • drugs • contractility • atrium
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Atrial fibrillation is a common arrhythmia associated with an increased risk of cardiovascular morbidity1 and mortality.2 Rapid, asynchronous atrial contractions during fibrillation result in a loss of atrial booster-pump function, which results in a decline in ventricular filling and cardiac output. The loss of a synchronized atrial contraction also leads to reduced atrial blood flow velocity, which favors the development of atrial thrombi.3 4 Accordingly, atrial fibrillation is the most frequent cause of cerebral embolism, accounting for 15% of all strokes.5 Conversion to sinus rhythm is therefore frequently attempted to improve cardiac performance and reduce the incidence of thrombus formation.
After conversion of atrial fibrillation, atrial contractility may be reduced or even absent for up to several weeks despite normal electric activity recorded by electrocardiogram.6 7 8 After cardioversion, the development of or an increase in left atrial and left atrial appendage spontaneous echocontrast, which is a swirling pattern of echo densities, is often observed.9 10 11 Spontaneous echocontrast has been shown to be strongly associated with left atrial appendage thrombus formation and embolic events10 11 12 and is related to reduced blood flow velocity with low shear rates and erythrocyte aggregation.13 Traditionally, it has been assumed that embolism in connection with cardioversion results from dislodgment of preexisting atrial thrombi after prompt return of atrial contraction. However, recent studies9 10 11 suggested that reduced contractility of the atrium or atrial appendage reduces atrial blood flow and also favors the development of atrial thrombi after cardioversion. Accordingly, improvement of atrial contractility after cessation of atrial fibrillation might reduce the risk of thrombus formation after cardioversion.
Factors that might contribute to reduced atrial contractility after cessation of atrial fibrillation, also termed atrial stunning, have been discussed.6 11 14 15 However, the mechanism is unknown, and no treatment has been suggested. Anesthesia and electric energy delivered during cardioversion may impair cardiac function, but reduced atrial contractility is also seen after pharmacological conversion.16 A primary atrial myocardial disease14 as well as a chronic rheumatic disease of the atrial myocardium15 have also been suggested to account for the delayed return of atrial contractility.
Reduced atrial contractility has been observed after short-term or paroxysmal atrial fibrillation.17 18 In a previous study,18 we demonstrated changes in atrial contractility after the cessation of periods of atrial fibrillation of 1 to 30 minutes in duration. The magnitude and duration of the reduced atrial contractility depended on the duration of the preceding atrial fibrillation. Surprisingly, we found that atrial contractility was increased in the first seconds after atrial fibrillation before a longer period of reduced atrial contractility ensued. On the basis of these observations, we hypothesized that cytosolic calcium overload due to the rapid depolarizations during the preceding fibrillation might be responsible for the atrial contractile dysfunction. This hypothesis had been suggested but not evaluated by Shapiro et al6 in 1988. It has been shown that cytosolic calcium increases with a high depolarization rate during regular pacing19 20 and that transient calcium overload may induce contractile dysfunction.21 22 Another suggested explanation for the contractile dysfunction is that the fibrillating atrial myocardium is ischemic because of high energy demand.6 After ischemia, both an initial hypercontractility and an ensuing hypocontractility have been observed.23
The first aim of the present study was to examine whether atrial contractile dysfunction after atrial fibrillation is influenced by drugs that alter the calcium influx via the sarcolemmal L-type calcium channels. Experiments were performed in open-chest, anesthetized pigs, and atrial fibrillation was induced by continuous rapid atrial pacing. By performing separate atrial and ventricular pacing after complete AV block,24 we were able to avoid the confounding effect of ventricular arrhythmia. We examined the effect of the calcium channel antagonist verapamil on postfibrillation atrial dysfunction. This drug is frequently used in the treatment of patients with acute and chronic atrial fibrillation. In addition, verapamil was considered particularly suitable for the purpose of reducing calcium influx during atrial fibrillation because its calcium antagonism increases with increasing frequency of depolarization.25 26 In a separate group of animals, we examined the effect of the calcium channel agonist BAY K8644 on postfibrillation dysfunction. BAY K8644 increases calcium influx through the L-type calcium channels.
The second aim of the present study was to determine whether atrial contractile dysfunction after cessation of fibrillation could be attributed to ischemia during atrial fibrillation. Thus, ATP, CrP, and lactate were measured in freeze-clamped biopsy samples from the atria before, during, and after atrial fibrillation in a separate group of animals.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Surgical Preparation
All experiments and animals were handled in accordance with the requirements set by the Norwegian Council for Animal Research. Twenty-five pigs of either sex (weight, 18 to 29 kg) were fasted for 24 hours and anesthetized with a bolus dose of pentobarbital sodium 25 mg/kg IP, which was supplemented by 5 to 20 mg · kg-1 · h-1 IV to maintain a constant level of anesthesia. The animals were ventilated via tracheostomy with a volume-regulated respirator (model 101, Princeton Medical Instruments). Oxygen supplement, tidal volume, and ventilation frequency were adjusted to keep arterial PO2, PCO2, and pH within normal ranges. The body temperature was kept constant by use of an electric heating pad and wrappings.
The heart was exposed through a midsternal split and an incision in the left fourth intercostal space. The pericardium was opened, and the heart was suspended in a pericardial cradle. The AV node was blocked by injection of 0.5 mL formalin 36% according to the method described by Steiner and Kovalik.24 The atria were paced by electrodes sutured to the right atrial appendage with a constant frequency slightly above the spontaneous heart rate. The ventricles were paced with the same frequency from the His bundle with 120-ms AV delay. The pacing electrodes were connected to a stimulator (model 5837, Medtronic Inc) that delivered 2-ms square-wave pulses of 10 V (double threshold value). Atrial fibrillation was induced by continuous stimulation of the right atrium at 15 Hz, as described previously,18 while the ventricular rate was kept unchanged.
A femoral artery and vein were cannulated for arterial blood gas sampling and intravenous infusions, respectively. Heparin (750 IU/kg) was given to prevent blood clotting in the pigs in the verapamil, BAY K8644, and control groups.
Hemodynamic Measurements
Hemodynamic measurements were obtained from the
18 pigs randomly assigned to receive verapamil or BAY K8644
or to serve as the control group. Left atrial cross-sectional
diameter was recorded by ultrasonic external-diameter
transducers (Triton Technology) sutured to the atrial surface as
previously described.27 Left atrial diameter was measured
as the diameter between the medial and lateral walls of the left
atrium. One transducer was placed near the pulmonary artery in
the groove between the aorta and the left atrium and the other on the
lateral surface of the atrium close to the left ventricle.
Two microtipped pressure-transducer catheters (model PC-40, Millar Instruments) were used to record pressure in the left atrium and left ventricle. Both catheters have a frequency response of 10 kHz. The catheter that was used to measure left atrial pressure was introduced through the left atrial appendage and secured by small purse-string sutures, and the catheter in the left ventricle was introduced via the right common carotid artery. Any drift in the pressure-recording system was detected by comparison with pressure recordings obtained through the fluid-filled side channels of the Millar catheters, connected to Statham P23 Gb pressure transducers (Gould Instruments). This system has a frequency response of 40 Hz. A fluid-filled catheter for arterial blood gas sampling was also introduced into the aorta via the right femoral artery and connected to a Statham P23 Gb transducer.
All hemodynamic variables were continuously monitored on an 8-channel galvanometric recorder (model 7758 B, Hewlett-Packard). On-line data acquisition and later analysis were written and performed in ASYST (Asyst Software Technologies, Inc), as described previously.18
Left atrial systolic shortening was computed as the difference
between the atrial diameter at the onset of the atrial A wave and the
atrial minimal diameter (Fig 1
). Since atrial
contractility depends on atrial preload, we calculated
the LASSindex as LASS divided by atrial preload (the atrial
diameter at onset of atrial contraction28 ). The value of
LASSindex before each period of atrial fibrillation was set
to 100%. Left atrial afterload was assessed from the left
ventricular segment–length recordings at the
onset of atrial contraction. The left ventricular segment
lengths measured a part of the ventricular wall
circumference and were obtained from one pair of ultrasonic transducers
sewn into the midmyocardium. One ultrasonic transmitter
and one ultrasonic receiver were placed 7 to 15 mm apart perpendicular
to the axis of contraction parallel to the first and second branches of
the left anterior descending coronary artery.
|
Experimental Design
The first 18 pigs in the present study were subjected to two
5-minute periods of atrial fibrillation separated by 1 hour of AV
pacing. The first period of atrial fibrillation was used as the
control. Recordings of hemodynamic
variables were obtained during AV pacing before each period of
atrial fibrillation and at 5, 15, and 30 seconds as well as 1, 2, 3, 4,
5, 10, 15, and 20 minutes after cessation of fibrillation. All atrial
parameters had returned to normal values before the second
period of fibrillation was initiated.
In the verapamil group (n=6), verapamil (0.2 mg/kg IV) was injected 60 minutes after the first period of atrial fibrillation. The second period of atrial fibrillation was initiated when the hemodynamic recordings reached a new steady state. In the BAY-K group (n=6), BAY K8644 (2.0 µg·kg-1·min-1 IV) was infused continuously throughout the recordings before and after the second atrial fibrillation period. In the control group (n=6), no drugs were given between the first and second atrial fibrillation periods. To compare the duration of atrial hypocontractility (LASSindex below the value obtained before fibrillation) within a group, the maximal reduction in LASSindex was determined. Thereafter, the time from the onset of atrial hypocontractility to the time when 80% restitution of contractility occurred was assessed. Heart rate was maintained at a constant level in each experiment, and there was no significant difference in heart rate between the groups.
Seven separate pigs were used for metabolic measurements. Because ATP concentrations do not fall early in ischemia and it takes time before lactate production occurs, a relative ischemia would be difficult to detect after 5 minutes of fibrillation. Accordingly, biopsy samples were obtained from the atrial myocardium during a control period, after 25 minutes of atrial fibrillation, and 30 minutes after cessation of atrial fibrillation. Lactate was also determined in atrial biopsy samples obtained after 10 minutes of left atrial ischemia. Ischemia was induced by ligation of the circumflex coronary artery, which supplies the left atrium in the pig.29 The biopsy samples were obtained by freeze-clamping the atrial tissue in vivo with pinchers cooled in liquid nitrogen (-70°C) and were stored at -70°C until analysis. Before analysis, each biopsy sample was dissected into two to three specimens, avoiding parts that macroscopically contained blood and fat. ATP, CrP, and lactate were determined enzymatically in 3 mol/L perchloric acid extracts neutralized by 2 mol/L potassium hydrogen carbonate. ATP and CrP contents were determined by luminescence,30 and lactate was determined by UV spectrophotometry.31 According to our measurements, minimum detection levels of ATP and lactate with a power of 0.8 would be 0.5 and 0.75 mmol/kg wet weight, respectively.
Statistics
Values are presented as mean±SEM. The Friedman
nonparametric ANOVA with an extension for multiple
comparisons32 was used for repeated measurements. The
Wilcoxon two-tailed signed rank test was used for paired
statistical analysis when two groups of data were compared. A
probability value of P<.05 was considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Verapamil Group
LASS was 5.9±0.5 mm during control conditions before atrial fibrillation (LASSindex 100%; Fig 2
). After
cessation of the 5-minute atrial fibrillation period, LASS immediately
increased to 6.9±0.4 mm, which corresponds to an increase in
LASSindex to 119.0±6.2%. The brief phase of atrial
hypercontractility (LASSindex>100%)
was followed by a period of atrial
hypocontractility (LASSindex<100%).
During this period of hypocontractility, LASS
reached a nadir of 4.7±0.6 mm (LASSindex 77.8±5.2%).
LASS remained below the control level for several minutes but gradually
increased and was not significantly different from control 10 minutes
after cessation of atrial fibrillation.
|
Left atrial preload and afterload were 30.6±1.6 and 10.2±1.1 mm, respectively, during control conditions and were not significantly different after cessation of fibrillation. Maximal left ventricular systolic pressure, its maximal positive first derivative (LV dP/dt), and mean aortic pressure were not significantly altered from the control values of 92±7 mm Hg, 1493±118 mm Hg/s, and 82±4 mm Hg, respectively.
Injection of verapamil reduced mean aortic pressure from 82±4 to 75±5 mm Hg. Maximal left ventricular systolic pressure and LV dP/dt declined from 95±5 to 89±7 mm Hg and from 1434±74 to 1184±46 mm Hg/s, respectively. However, injection of verapamil did not significantly affect LASS, atrial preload, or left ventricular segment length.
After injection of verapamil, LASS was 6.2±0.5 mm before
atrial fibrillation and 6.9±0.4 mm immediately after cessation of
fibrillation (P=NS). LASSindex increased
immediately after fibrillation to 108.8±3.6% (P<.05) (Fig 2
). Thereafter, a period of atrial
hypocontractility ensued. However, the magnitude of
the atrial hypocontractility was significantly
reduced. During this period of hypocontractility,
LASS reached a nadir of 5.6±0.5 mm (LASSindex 92.5±2.4%)
after verapamil, compared with 4.7±0.6 mm
(LASSindex 77.8±5.2%) before verapamil
(P<.05). Verapamil also reduced the duration of
atrial hypocontractility, and LASSindex
was not significantly different from control by 2 minutes after
fibrillation. Before verapamil, time to 80% restitution of
atrial contractility was 6.9±0.9 minutes. After
verapamil, this was significantly reduced to 2.5±0.7
minutes (P<.05). After cessation of fibrillation, left
atrial preload and afterload were not significantly different from the
values of 30.7±5.0 and 10.2±1.2 mm, respectively, obtained before
atrial fibrillation. Similarly, mean aortic pressure, maximal left
ventricular systolic pressure, and LV dP/dt were
not significantly altered after fibrillation.
BAY K8644 Group
During control conditions, LASS was 5.2±0.4 mm before
atrial fibrillation (LASSindex 100%; Fig 3). After the 5-minute atrial fibrillation period, LASS
immediately increased to 5.7±0.3 mm, which corresponds to an increase
in LASSindex to 108.0±3.0% 5 seconds after fibrillation.
This brief hypercontractile phase was followed by a period of atrial
hypocontractility. During this hypocontractile
period, LASS reached a nadir of 4.1±0.6 mm (LASSindex
76.6±7.7%). LASS remained below control values in the next few
minutes but gradually increased and was not significantly different
from control after 10 minutes.
|
Atrial preload and afterload were 28.7±1.2 and 9.4±04 mm, respectively, during control conditions and were not significantly different after cessation of the 5-minute atrial fibrillation period. Similarly, after fibrillation, there were no significant alterations in mean aortic pressure, maximal left ventricular systolic pressure, and LV dP/dt from the respective values of 95±4 mm Hg, 111±8 mm Hg, and 1720±221 mm Hg/s obtained before fibrillation.
When steady state was reached during infusion of BAY K8644, mean aortic pressure had increased from 96±5 to 114±6 mm Hg. Maximal left ventricular systolic pressure increased from 112±7 to 145±7 mm Hg and LV dP/dt from 1744±213 to 2213±320 mm Hg/s. LASS increased from 5.1±1.3 to 6.8±0.3 mm. Left atrial preload and left ventricular segment length, however, were not different from the values (29.0±1.2 mm and 9.5±04 mm) obtained before infusion of BAY K8644.
When atrial fibrillation was induced during infusion of BAY K8644,
postfibrillation atrial dysfunction was aggravated compared with before
BAY-K infusion. LASS was 6.8±0.3 mm during BAY-K infusion before
atrial fibrillation. After cessation of atrial fibrillation, the
increase in LASS to 7.1±0.2 mm (LASSindex 105.2±6.0%;
Fig 3) did not reach statistical significance. However, a period of
marked atrial hypocontractility ensued, and LASS
declined below control levels to a nadir of 4.7±0.7 mm
(P<.05). The postfibrillation nadir in
LASSindex was 67.9±7.6%, which was significantly lower
than the value of 76.6±7.7% obtained before infusion of BAY K8644
(P<.05). Thereafter, LASS gradually increased and was not
significantly different from control after 15 minutes. Before infusion
of BAY K8644, time to 80% restitution in atrial
contractility after cessation of atrial fibrillation
was 8.1±1.2 minutes. This was significantly increased to 15.9±3.0
minutes during infusion of BAY K8644. Thus, BAY K8644 significantly
aggravated both the magnitude and duration of postfibrillation atrial
dysfunction. After cessation of fibrillation, left atrial preload and
afterload were not significantly different from the values of 29.6±1.6
mm and 9.4±0.4 mm obtained before atrial fibrillation. Similarly, mean
aortic pressure, maximal left ventricular systolic
pressure, and LV dP/dt did not change from before to after cessation of
fibrillation.
Control Group
LASS was 5.8±0.6 mm before each period of atrial fibrillation.
Five seconds after the first fibrillation period, LASS increased to
6.9±0.4 mm, corresponding to an increase in LASSindex to
121.0±6.3%. After the second fibrillation period, LASS increased to
6.8±0.3 mm (LASSindex 119.0±6.2%), which was not
significantly different from the hypercontractility
observed after the first fibrillation period. This brief phase of
atrial hypercontractility was followed by a
5-minute period of atrial hypocontractility after
both the first and second fibrillation periods. After the first
fibrillation period, LASS reached a nadir of 4.1±0.6 mm by 15 seconds
after fibrillation, corresponding to a minimum LASSindex
value of 69.5±4.9%. After the second atrial fibrillation period, LASS
decreased to a nadir of 4.0±0.6 mm (LASSindex
68.3±4.8%). Time to 80% restitution of atrial
contractility after atrial fibrillation was not
significantly different between the first and second fibrillation
periods. Thus, the changes in LASS and LASSindex after the
first and second atrial fibrillation periods were not significantly
different.
After cessation of the first atrial fibrillation period, left atrial preload and afterload remained unchanged from the values of 30.2±2.7 and 8.4±0.5 mm obtained before fibrillation. Similarly, mean aortic pressure, left ventricular systolic pressure, and LV dP/dt did not change from the respective values of 84±6 mm Hg, 100±4 mm Hg, and 1782±193 mm Hg/s after fibrillation. There were no statistical differences between the control values of any of these hemodynamic variables obtained before the first and second fibrillation periods or between the control values and the values obtained after the second atrial fibrillation period.
Metabolites in Atrial Myocardium
Figs 4, 5, and 6 show
the atrial tissue content of CrP, ATP, and lactate, respectively,
during control conditions before atrial fibrillation, after 25 minutes
of atrial fibrillation, and 30 minutes after cessation of fibrillation.
The content of CrP in atrial myocardium was 4.5±0.5
mmol · kg ww-1 during control conditions and was
slightly but significantly reduced during atrial fibrillation. After 25
minutes of atrial fibrillation, CrP had decreased to 3.4±0.4
mmol · kg ww-1 (P<.001). After 25 minutes
of recovery after cessation of fibrillation, CrP returned to its
control value. During atrial fibrillation, ATP and lactate did not
change significantly from the respective control values of 2.9±0.2 and
2.6±0.3 mmol · kg ww-1 obtained before fibrillation.
After 10 minutes of left atrial ischemia, however, the atrial
tissue content of lactate increased to 9.2±0.9 mmol · kg
ww-1.
|
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study is the first to demonstrate that atrial dysfunction after cessation of atrial fibrillation is influenced by drugs that affect the L-type calcium channels. Atrial contractile dysfunction after cessation of short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. There is no apparent ischemia of the atrial myocardium during short-term atrial fibrillation.
Effects of Verapamil on Postfibrillation Atrial
Dysfunction
Verapamil reduced both the magnitude and the duration
of atrial hypocontractility after cessation of
atrial fibrillation. The reduced postfibrillation atrial contractile
dysfunction was most likely due to partial blockade of the L-type
calcium channels by verapamil. Blockade of these channels
probably reduces intracellular calcium overload in atrial myocytes
during fibrillation.
A high depolarization rate is accompanied by elevated cytosolic calcium in vitro, both during pacing19 20 and during spontaneous tachycardia.33 An increase in cytosolic calcium also has been demonstrated with irregularity of depolarization.34 Like atrial fibrillation, ventricular fibrillation is characterized by frequent, irregular contractions, and an increase in intracellular calcium has been demonstrated in the fibrillating ventricle even in the absence of ischemia.22
Several factors may contribute to an increase in cytosolic calcium with increased depolarization frequency. At higher rates, both sodium and calcium influxes via L-type calcium channels are expected to be greater, because there are more action potentials per unit of time. The sarcoplasmic reticulum would be loaded with calcium at high rates and respond to a depolarization by an increased calcium release to the cytosol. Extrusion of calcium from the cell occurs mainly via the sodium-calcium exchanger. At high heart rates, however, both increased intracellular sodium and more positive membrane potentials tend to result in net calcium influx.35
An intracellular calcium overload may account for both the observed initial atrial hypercontractility and the ensuing period of atrial hypocontractility after cessation of atrial fibrillation. With a calcium overload in the fibrillating atrial myocytes, cytosolic calcium would be elevated the first few seconds after cessation of fibrillation, which would explain the brief, initial period of atrial hypercontractility that was observed. Transient exposure to high cytosolic calcium without ischemia induces distinctive contractile dysfunction,21 which was also observed after ventricular fibrillation in the study by Koretsune and Marban.22 Recent studies suggest that the contractile dysfunction observed after transient calcium overload is at least partly due to reduced calcium sensitivity,21 36 which probably resides at the level of the contractile proteins.37 38 The functional changes have been related to myofilament proteolysis, possibly of the thin-filament regulatory protein troponin I.37 39 Hence, a reduction in elevated cytosolic calcium during fibrillation by verapamil might be expected to diminish reduced calcium sensitivity after fibrillation.
Verapamil is a phenylalkylamine that antagonizes transsarcolemmal calcium influx by decreasing the open-time probability of the L-type calcium channels. This calcium antagonism is voltage and frequency dependent,25 26 and verapamil therefore would be expected to exert greater inhibition at the rapid atrial depolarizations during atrial fibrillation. Thus, reduced transient calcium overload during atrial fibrillation by pretreatment with verapamil might explain both the reduction in the initial, brief period of atrial hypercontractility and the reduction in the ensuing atrial hypocontractility observed in the present study.
Atrial contractility is influenced by atrial preload40 41 and afterload.42 43 In the present study, there were no changes in atrial preload or afterload (left atrial diameter and left ventricular segment length at the onset of atrial contraction) from before to after fibrillation either during control conditions or after pretreatment with verapamil. Furthermore, there were no changes in these variables during the periods of atrial hypercontractility and hypocontractility. The hypercontractile and hypocontractile phases of atrial contractility were also observed after ß-blockade in a previous study18 ; thus, changes in cardiac sympathetic stimulation are unlikely to explain our findings.
After injection of verapamil, there was a small decrease in mean arterial pressure, as would be anticipated from its vasodilatory effect. The small declines in left ventricular pressure and LV dP/dt are probably due to the negative inotropic effect of verapamil. However, because we observed no changes in left atrial afterload or preload after administration of verapamil, changes in left ventricular hemodynamics and peripheral vascular effects are unlikely to explain the effects of verapamil on postfibrillation atrial dysfunction. Moreover, atrial contractility remained unchanged after verapamil, probably because of a reflex sympathetic stimulation caused by the fall in arterial pressure.
Effects of BAY K8644 on Postfibrillation Atrial
Dysfunction
BAY K8644 increased both the magnitude and the duration of atrial
hypocontractility after cessation of atrial
fibrillation. The increased postfibrillation atrial contractile
dysfunction was most likely due to the agonistic effect of BAY K8644 on
the L-type calcium channels, which probably leads to intracellular
calcium overload in atrial myocytes during fibrillation. The
dihydropyridine calcium channel agonist BAY K8644
binds to the L-type calcium channel in a state-independent and
thereby voltage-independent manner,44 which favors a
more prolonged open state of the channel and thereby increases the
inward calcium current.44 45 Hence, BAY K8644 would be
expected to promote the influx of calcium during each contraction in
the fibrillating atrium. Thus, the detrimental effect of BAY K8644 on
atrial contractility after fibrillation supports the
hypothesis that intracellular calcium overload during atrial
fibrillation is the mechanism for postfibrillation atrial
dysfunction.
Intravenous administration of BAY K8644 produces an increase in arterial blood pressure, left ventricular systolic pressure, and peak positive LV dP/dt,46 as demonstrated in the present study. Atrial preload, however, was unaltered after BAY K8644 infusion. Moreover, BAY K8644 did not alter left ventricular segment length at the onset of atrial contraction.
During infusion of BAY K8644, there were no changes in atrial preload or afterload (left atrial diameter and left ventricular segment length at the onset of atrial contraction) from before to after fibrillation. Furthermore, there were no changes in these parameters during the periods of atrial hypercontractility and hypocontractility after fibrillation. Finally, the effect of BAY K8644 on postfibrillation contractile dysfunction cannot be ascribed to the effect of repetitive atrial fibrillation periods, as there was no significant difference in atrial dysfunction after the first and second fibrillation periods in the control group.
Metabolic Adjustments During Atrial
Fibrillation
Atrial fibrillation is a high energy–demanding state, and it
has been suggested that the gradual improvement in atrial contractile
dysfunction after atrial fibrillation may represent the
functional recovery of postischemic atrial
myocardium.6 Both a brief increase in
ventricular contractility23
and a period of ventricular
hypocontractility, known as
stunning,47 have been observed after ischemia.
However, conflicting evidence exists as to whether atrial myocytes are
ischemic during atrial fibrillation.48 49 Smetnev
et al48 reported myocardial lactate production in
the majority of patients with chronic atrial fibrillation and normal
coronary angiography. In contrast, Lau et al49
found unchanged arterial and coronary sinus lactate
concentrations after 5 minutes of induced atrial fibrillation in
patients with paroxysmal atrial fibrillation. During atrial
fibrillation, atrial blood flow increases twofold to
threefold.50 Furthermore, the atrial vasodilator reserve
is reduced but not abolished51 during atrial fibrillation.
Thus, measurements of atrial blood flow have not established whether a
relative atrial ischemia is present during atrial
fibrillation.
The present study demonstrates that atrial dysfunction after cessation of short-term atrial fibrillation is not due to ischemia during the preceding fibrillation. During atrial fibrillation, ATP and lactate were unchanged from the control values obtained before and the recovery values obtained after atrial fibrillation. The small but significant decrease in CrP probably reflects the increased metabolism in the atrial myocardium during fibrillation. This assumption is supported by the fact that atrial oxygen consumption is increased during fibrillation.50
Clinical Implications
In patients, atrial fibrillation may be paroxysmal or chronic.
Paroxysmal attacks may last for minutes or for days, and
verapamil is widely used both in patients with paroxysmal
and in those with chronic atrial fibrillation. The present data on
short-term atrial fibrillation cannot be related to all patients
without reservation, but a pharmacological agent that would safely
improve contractile function of the atrial myocardium after
fibrillation might be of clinical benefit.
It is presently unknown whether the same mechanism accounts for atrial contractile dysfunction after short-term, paroxysmal, and chronic atrial fibrillation. During chronic atrial fibrillation, Borgers et al52 demonstrated in a recent study that after 2 to 3 months of sustained atrial fibrillation in goats, 80% of the atrial myocardial cells had undergone dedifferentiation. There was loss of myofibrils, accumulation of glycogen, changes in mitochondrial size and shape, fragmentation of sarcoplasmic reticulum, and dispersion of nuclear chromatin. These structural changes seen in atrial myocytes resemble those seen in chronic hibernating myocardium in humans, which is a condition in which elevated amounts of cytosolic calcium have been documented.53 In patients with chronic atrial fibrillation, degenerative changes and atrophy of the atrial myocytes, as well as interstitial fibrosis, have been described.54 55 Although such structural changes of the atrial myocardium may be reversible after cessation of fibrillation, it would take time to rebuild a normal contractile apparatus. This might explain the delay in recovery of atrial contractile function observed in patients after conversion of chronic atrial fibrillation. Another factor that may contribute to postfibrillation contractile dysfunction in patients with chronic atrial fibrillation is a depressed baroreflex sensitivity. However, no change in baroreflex function was observed in an experimental study after 6 weeks of atrial fibrillation.56
During the period of atrial contractile dysfunction after cardioversion of atrial fibrillation, thromboembolic complications have been reported to occur despite the absence of demonstrable atrial thrombi by transesophageal echocardiography performed before conversion.10 11 Because embolisms do not occur immediately but tend to occur over a period of days after cardioversion,10 57 it is reasonable to believe that thrombus formation develops because of the reduced contractility of the atrium after cardioversion.9 10 11 The present study shows that pretreatment with verapamil before atrial fibrillation reduces postfibrillation atrial dysfunction. Further studies are needed, however, to evaluate the possible pharmacological implications of this finding in patients with atrial fibrillation.
Conclusions
The present study demonstrates that atrial contractile
dysfunction after short-term atrial fibrillation is reduced by
pretreatment with the calcium antagonist
verapamil, which suggests that transsarcolemmal calcium
influx contributed to this dysfunction. The calcium agonist BAY K8644
increased postfibrillation atrial contractile dysfunction. Atrial
ischemia was not observed during fibrillation, which indicates
that postfibrillation atrial dysfunction cannot be attributed to
postischemic stunning in the present study.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
This work was supported by grants from the Anders Jahres Fund for the Promotion of Science, the Carl Sembs Fund, and legacies of the University of Oslo. We thank Hilde Hyldmo, Severin Leraand, and Turid Verpe for technical assistance and Sonja T. Flagestad and Heidi S. Kvalø for secretarial work.
Received July 12, 1995; revision received October 30, 1995; accepted November 15, 1995.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28:973-977.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018-1022. [Abstract]
3.
Pollick C, Taylor D. Assessment of left atrial
appendage function by transesophageal
echocardiography: implications for the development
of thrombus. Circulation. 1991;84:223-231.
4. Fatkin D, Feneley MP, Kelly RP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol. 1994;23:961-969. [Abstract]
5.
Wolf PA, Abbott RD, Kannel WB. Atrial
fibrillation as an independent risk factor for stroke: the Framingham
Study. Stroke. 1991;22:983-988.
6. Shapiro EP, Effron MB, Lima S, Ouyang P, Siu CO, Bush D. Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. Am J Cardiol. 1988;62:1202-1207. [Medline] [Order article via Infotrieve]
7. Manning WJ, Leeman DE, Gotch PJ, Come PC. Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol. 1989;13:617-623. [Abstract]
8. Van Gelder IC, Crijns HJGM, Blanksma PK, Landsman MLJ, Posma JL, Van Den Berg MP, Meijler FL, Lie KI. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Circulation. 1994;72:560-566.
9. Grimm RA, Stewart WJ, Maloney JD, Cohen GI, Pearce GL, Salcedo EE, Klein AL. Impact of electrical cardioversion for atrial fibrillation on left atrial appendage function and spontaneous echo contrast: characterization by simultaneous transesophageal echocardiography. J Am Coll Cardiol. 1993;22:1359-1366. [Abstract]
10.
Black IW, Fatkin D, Sagar KB, Khanderia BK, Leung DY,
Galloway JM, Feneley MP, Walsh WF, Grimm RA, Stollberger C, Verhorst
PMJ, Klein AL. Exclusion of atrial thrombus by
transesophageal echocardiography
does not preclude embolism after cardioversion of atrial
fibrillation. Circulation. 1994;89:2509-2513.
11. Fatkin D, Kuchar DL, Thorburn CW, Feneley MP. Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for `atrial stunning' as a mechanism of thromboembolic complications. J Am Coll Cardiol. 1994;23:307-316. [Abstract]
12. Leung DYC, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol. 1994;24:755-762. [Abstract]
13. Fatkin D, Herbert E, Feneley MP. Hematologic correlates of spontaneous echo contrast in patients with atrial fibrillation and implications for thromboembolic risk. Am J Cardiol. 1994;73:672-676. [Medline] [Order article via Infotrieve]
14. Graettinger JS, Carleton RA, Muenster JJ. Circulatory consequences of changes in cardiac rhythm produced in patients by transthoracic direct-current shock. J Clin Invest. 1964;43:2290-2302.
15. Logan WFWE, Rowlands DJ, Howitt G, Holmes AM. Left atrial activity following cardioversion. Lancet. 1965;2:471-473. [Medline] [Order article via Infotrieve]
16. Dethy M, Chassat C, Roy D, Mercier L-A. Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol. 1988;62:723-726. [Medline] [Order article via Infotrieve]
17. Macierho-Coelho E, Alves MG, Granate J, Coelho E. Atrial activity following conversion of experimental atrial fibrillation by direct current shock. Acta Cardiol. 1968;23:439-453. [Medline] [Order article via Infotrieve]
18.
Leistad E, Christensen G, Ilbekk A. Atrial
contractile performance after cessation of atrial
fibrillation. Am J Physiol. 1993;264:H104-H109.
19.
Lee H-C, Clusin WT. Cytosolic calcium staircase
in cultured myocardial cells. Circ Res. 1987;61:934-939.
20. Schouten VJA, Morad M. Regulation of Ca2+ current in frog ventricular myocytes by the holding potential, c-AMP and frequency. Pflugers Arch. 1989;415:1-11. [Medline] [Order article via Infotrieve]
21.
Kitakaze M, Weisman HF, Marban E. Contractile
dysfunction and ATP depletion after transient calcium overload in
perfused ferret hearts. Circulation. 1988;77:685-695.
22.
Koretsune Y, Marban E. Cell calcium in the
pathophysiology of ventricular fibrillation and in the
pathogenesis of postarrhythmic contractile dysfunction.
Circulation. 1989;80:369-379.
23.
Pagani M, Vatner SF, Baig H, Braunwald E.
Initial myocardial adjustments to brief periods of ischemia and
reperfusion in the conscious dog. Circ
Res. 1978;43:83-92.
24.
Steiner C, Kovalik TW. A simple technique for
production of chronic complete heart block in dogs.
J Appl Physiol. 1968;25:631-632.
25. Bayer R, Kaufmann R, Mannhold D. Inotropic and electrophysiological actions of verapamil and D 600 in mammalian myocardium, I: pattern of inotropic effects of the racemic compounds. Naunyn Schmiedebergs Arch Pharmacol. 1975;290:49-68. [Medline] [Order article via Infotrieve]
26.
Ehara T, Daufman R. The voltage- and
time-dependent effects of (–)-verapamil on the slow
inward current in isolated ventricular
myocardium. J Pharmacol Exp
Ther. 1978;207:49-55.
27.
Leistad E, Christensen G, Ilebekk A. Right and
left atrial diameters during incremental atrial pacing in pigs.
Am J Physiol. 1991;260:H973-H978.
28.
Recordati G, Lombardi F, Malliani A, Brown
AM. Instantaneous dimensional changes of the right atrium in the
cat. J Appl Physiol. 1974;36:686-692.
29.
Christensen G, Aksnes G, Ilebekk A, Kiil F.
Release of atrial natriuretic factor during selective
cardiac 
- and ß-adrenergic stimulation,
intracoronary Ca2+ infusion, and aortic
constriction in pigs. Circ Res. 1991;68:638-644.
30. Lundin A, Rickardsson A, Thore A. Continuous monitoring of ATP-converting reactions by purified firefly luciferase. Anal Biochem. 1976;75:611-620. [Medline] [Order article via Infotrieve]
31. Lowry OH, Passonneau JV. A Flexible System of Enzymatic Analysis. New York, NY: Academic Press; 1972:146-201.
32. Conover WJ. Practical Nonparametric Statistics. 2nd ed. New York, NY: John Wiley & Sons; 1980:299-300.
33.
Thandroyen FT, Morris AC, Hagler HK, Ziman B, Pai L,
Willerson JT, Buja LM. Intracellular calcium transients and
arrhythmia in isolated heart cells.
Circ Res. 1991;69:810-819.
34.
Wier WG, Yue DT. Intra-cellular calcium
transients underlying the short-term force-interval
relationship in ferret ventricular
myocardium. J Physiol (Lond). 1986;376:507-530.
35. Boyett MR, Frampton JE, Harrison SM, Kirby MS, Levi AJ, McCall E, Milner DR, Orchard CH. The role of intracellular calcium, sodium and pH in rate-dependent changes of cardiac contractile force. In: Noble MIM, Seed WA, eds. The Interval-Force Relationship of the Heart: Bowditch Revisited. New York, NY: Cambridge University Press; 1992:111-172.
36.
Kusuoka H, Koretsune Y, Chacko VP, Weisfeldt ML, Marban
E. Excitation-contraction coupling in
postischemic myocardium: does failure of
activator Ca2+ transients underlie
stunning? Circ Res. 1990;66:1268-1276.
37. Gao WD, Atar D, Backx PH, Marban E. Direct measurements of the Ca2+ responsiveness of the contractile proteins in intact stunned myocardium. Circulation. 1994;90(suppl I):I-646. Abstract.
38. Atar D, Gao WD, Backx PH, Murphy AM, Marban E. Immunoblot analysis of stunned myocardium reveals structural alterations of the myofilaments predicted by modeling of cross-bridged kinetics. Circulation. 1994;90(suppl I):I-646. Abstract.
39. McDonald KS, Lewis NK, Greaser M, Moss RL, Miller WP. Alteration in the troponin regulatory complex of postischemic stunned porcine myocardium results in decreased myofilament Ca2+ sensitivity. Circulation. 1994;90(suppl I):I-646. Abstract.
40. Williams JF Jr, Sonnenblick EH, Braunwald E. Determinants of atrial contractile force in the intact heart. Am J Physiol. 1965;209:1061-1068.
41.
Payne RM, Stone HL, Engelken EJ. Atrial function
during volume loading. J Appl Physiol. 1971;31:326-331.
42. Goldman S, Olajos M, Morkin E. Comparison of left atrial and left ventricular performance in conscious dogs. Cardiovasc Res. 1984;18:604-612. [Medline] [Order article via Infotrieve]
43. Matsuzaki M, Tamitani M, Toma Y, Ogawa H, Katayama K, Matsuda Y, Kusukawa R. Mechanism of augmented left atrial pump function in myocardial infarction and essential hypertension evaluated by left atrial pressure-dimension relation. Am J Cardiol. 1991;67:1121-1126. [Medline] [Order article via Infotrieve]
44. Bechem M, Hoffman H. The molecular mode of action of the Ca agonist (–) Bay K 8644 on the cardiac Ca channel. Pflugers Arch. 1993;424:343-353. [Medline] [Order article via Infotrieve]
45. Hess P, Lansman JB, Tsien RW. Different modes of Ca channel gating behaviour favoured by dihydropyidine Ca agonists and antagonists. Nature. 1984;311:538-544. [Medline] [Order article via Infotrieve]
46. Schramm M, Thomas G, Towart R, Franckowiak G. Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature. 1983;303:535-537. [Medline] [Order article via Infotrieve]
47. Heyndrickx GR, Millard RW, McRitchie RJ, Maroko PR, Vatner SF. Regional myocardial function and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest. 1975;56:978-985.
48. Smetnev AS, Bunin I, Nargizian AB, Petrovskii PF, Vakhliaev VD. Characteristics in the metabolism in the myocardium of patients with auricular fibrillation. Kardiologiia. 1983;23:70-73.
49.
Lau C-P, Leung W-H, Wong C-K, Cheng C-H.
Haemodynamics of induced atrial fibrillation: a comparative assessment
with sinus rhythm, atrial and ventricular pacing.
Eur Heart J. 1990;11:219-224.
50.
White CW, Kerber RE, Weiss HR, Marcus ML. The
effects of atrial fibrillation on atrial pressure-volume and flow
relationships. Circ Res. 1982;51:205-215.
51. White CW, Holida MD, Marcus ML. Effects of acute atrial fibrillation on the vasodilator reserve of the canine atrium. Cardiovasc Res. 1986;20:683-689.[Medline] [Order article via Infotrieve]
52. Borgers M, Ausma J, Wijffels M, Allessie M. Atrial fibrillation in the goat: a model for chronic hibernating myocardium. Circulation. 1994;90(suppl I):I-467. Abstract.
53. Borgers M, De Nollin S, Thonè F, Wouters L, VanVaeck L, Flameng W. Distribution of calcium in a subset of chronic hibernating myocardium in man. Histochem J. 1993;25:312-318. [Medline] [Order article via Infotrieve]
54.
Davies MJ, Pomerance A. Pathology of atrial
fibrillation in man. Br Heart J. 1972;34:520-525.
55.
Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio
JJ, Malm JR, Rosen MR. The relationship of human atrial cellular
electrophysiology to clinical function and ultrastructure.
Circ Res. 1983;52:188-199.
56.
Morillo CA, Klein GJ, Jones DL, Guiraudon CM.
Chronic rapid atrial pacing: structural, functional, and
electrophysiological characteristics of a
new model of sustained atrial fibrillation.
Circulation. 1995;91:1588-1595.
57. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23:208-216.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  X. Y. Qi, Y.-H. Yeh, L. Xiao, B. Burstein, A. Maguy, D. Chartier, L. R. Villeneuve, B. J.J.M. Brundel, D. Dobrev, and S. Nattel Cellular Signaling Underlying Atrial Tachycardia Remodeling of L-type Calcium Current Circ. Res., October 10, 2008; 103(8): 845 - 854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nattel, A. Maguy, S. Le Bouter, and Y.-H. Yeh Arrhythmogenic Ion-Channel Remodeling in the Heart: Heart Failure, Myocardial Infarction, and Atrial Fibrillation Physiol Rev, April 1, 2007; 87(2): 425 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Vest, X. H.T. Wehrens, S. R. Reiken, S. E. Lehnart, D. Dobrev, P. Chandra, P. Danilo, U. Ravens, M. R. Rosen, and A. R. Marks Defective Cardiac Ryanodine Receptor Regulation During Atrial Fibrillation Circulation, April 26, 2005; 111(16): 2025 - 2032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shiroshita-Takeshita, G. Schram, J. Lavoie, and S. Nattel Effect of Simvastatin and Antioxidant Vitamins on Atrial Fibrillation Promotion by Atrial-Tachycardia Remodeling in Dogs Circulation, October 19, 2004; 110(16): 2313 - 2319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Veenhuyzen, C. S. Simpson, and H. Abdollah Atrial fibrillation Can. Med. Assoc. J., September 28, 2004; 171(7): 755 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J.J.M Brundel, H. H Kampinga, and R. H Henning Calpain inhibition prevents pacing-induced cellular remodeling in a HL-1 myocyte model for atrial fibrillation Cardiovasc Res, June 1, 2004; 62(3): 521 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sanders, J. B. Morton, P. M. Kistler, J. K. Vohra, J. M. Kalman, and P. B. Sparks Reversal of Atrial Mechanical Dysfunction After Cardioversion of Atrial Fibrillation: Implications for the Mechanisms of Tachycardia-Mediated Atrial Cardiomyopathy Circulation, October 21, 2003; 108(16): 1976 - 1984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schotten, M. Duytschaever, J. Ausma, S. Eijsbouts, H.-R. Neuberger, and M. Allessie Electrical and Contractile Remodeling During the First Days of Atrial Fibrillation Go Hand in Hand Circulation, March 18, 2003; 107(10): 1433 - 1439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sanders, J. B. Morton, J. G. Morgan, N. C. Davidson, S. J. Spence, J. K. Vohra, J. M. Kalman, and P. B. Sparks Reversal of Atrial Mechanical Stunning After Cardioversion of Atrial Arrhythmias: Implications for the Mechanisms of Tachycardia-Mediated Atrial Cardiomyopathy Circulation, October 1, 2002; 106(14): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goette, M. Arndt, C. Rocken, T. Staack, R. Bechtloff, D. Reinhold, C. Huth, S. Ansorge, H. U. Klein, and U. Lendeckel Calpains and cytokines in fibrillating human atria Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H264 - H272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Allessie, J. Ausma, and U. Schotten Electrical, contractile and structural remodeling during atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 230 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J.J.M. Brundel, R. H. Henning, H. H. Kampinga, I. C. Van Gelder, and H. J.G.M. Crijns Molecular mechanisms of remodeling in human atrial fibrillation Cardiovasc Res, May 1, 2002; 54(2): 315 - 324. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management? Cardiovasc Res, May 1, 2002; 54(2): 347 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinagawa, H. Mitamura, S. Ogawa, and S. Nattel Effects of inhibiting Na+/H+-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling Cardiovasc Res, May 1, 2002; 54(2): 438 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kurita, H. Mitamura, A. Shiroshita-Takeshita, A. Yamane, M. Ieda, O. Kinebuchi, T. Sato, S. Miyoshi, M. Hara, S. Takatsuki, et al. Daily oral verapamil before but not after rapid atrial excitation prevents electrical remodeling Cardiovasc Res, May 1, 2002; 54(2): 447 - 455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schotten, M. Greiser, D. Benke, K. Buerkel, B. Ehrenteidt, C. Stellbrink, J. F Vazquez-Jimenez, F. Schoendube, P. Hanrath, and M. Allessie Atrial fibrillation-induced atrial contractile dysfunction: a tachycardiomyopathy of a different sort Cardiovasc Res, January 1, 2002; 53(1): 192 - 201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L.J.L. Thijssen, J. Ausma, and M. Borgers Structural remodelling during chronic atrial fibrillation: act of programmed cell survival Cardiovasc Res, October 1, 2001; 52(1): 14 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. BERTAGLIA, D. D'ESTE, A. ZANOCCO, F. ZERBO, and P. PASCOTTO Effects of pretreatment with verapamil on early recurrences after electrical cardioversion of persistent atrial fibrillation: a randomised study Heart, May 1, 2001; 85(5): 578 - 580. [Full Text]
|
|
|
|
|
|
H. Sun, D. Chartier, N. Leblanc, and S. Nattel Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes Cardiovasc Res, March 1, 2001; 49(4): 751 - 761. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fareh, A. Benardeau, and S. Nattel Differential efficacy of L- and T-type calcium channel blockers in preventing tachycardia-induced atrial remodeling in dogs Cardiovasc Res, March 1, 2001; 49(4): 762 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. T. Altemose, D. P. Zipes, J. Weksler, J. M. Miller, and J. E. Olgin Inhibition of the Na+/H+ Exchanger Delays the Development of Rapid Pacing-Induced Atrial Contractile Dysfunction Circulation, February 6, 2001; 103(5): 762 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Stefanadis, J. Dernellis, and P. Toutouzas A clinical appraisal of left atrial function Eur. Heart J., January 1, 2001; 22(1): 22 - 36. [PDF]
|
|
|
|
 |
|
 H. S. Friedman, M. Win, A. Hussain, and A. Sinha Effects of Cardiac Glycosides on Atrial Contractile Dysfunction After Short-term Atrial Fibrillation Chest, October 1, 2000; 118(4): 1116 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel and D. Li Ionic Remodeling in the Heart : Pathophysiological Significance and New Therapeutic Opportunities for Atrial Fibrillation Circ. Res., September 15, 2000; 87(6): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ausma, W. A Coumans, H. Duimel, G. J Van der Vusse, M. A Allessie, and M. Borgers Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fibrillation Cardiovasc Res, September 1, 2000; 47(4): 788 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Barbier, S. Solomon, N. B. Schiller, and S. A. Glantz Determinants of forward pulmonary vein flow: An open pericardium pig model J. Am. Coll. Cardiol., June 1, 2000; 35(7): 1947 - 1959. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Jayachandran, D. P. Zipes, J. Weksler, and J. E. Olgin Role of the Na+/H+ Exchanger in Short-Term Atrial Electrophysiological Remodeling Circulation, April 18, 2000; 101(15): 1861 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fareh, A. Benardeau, B. Thibault, and S. Nattel The T-Type Ca2+ Channel Blocker Mibefradil Prevents the Development of a Substrate for Atrial Fibrillation by Tachycardia-Induced Atrial Remodeling in Dogs Circulation, November 23, 1999; 100(21): 2191 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tessier, P. Karczewski, E.-G. Krause, Y. Pansard, C. Acar, M. Lang-Lazdunski, J.-J. Mercadier, and S. N. Hatem Regulation of the Transient Outward K+ Current by Ca2+/Calmodulin-Dependent Protein Kinases II in Human Atrial Myocytes Circ. Res., October 29, 1999; 85(9): 810 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sparks, H. G. Mond, J. K. Vohra, A. G. Yapanis, L. E. Grigg, and J. M. Kalman Mechanical Remodeling of the Left Atrium After Loss of Atrioventricular Synchrony : A Long-Term Study in Humans Circulation, October 19, 1999; 100(16): 1714 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nakatani, M. J. Garcia, M. S. Firstenberg, L. Rodriguez, R. A. Grimm, N. L. Greenberg, P. M. McCarthy, P. M. Vandervoort, and J. D. Thomas Noninvasive assessment of left atrial maximum dP/dt by a combination of transmitral and pulmonary venous flow J. Am. Coll. Cardiol., September 1, 1999; 34(3): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Daoud, P. Marcovitz, B. P. Knight, R. Goyal, K. C. Man, S. A. Strickberger, W. F. Armstrong, and F. Morady Short-Term Effect of Atrial Fibrillation on Atrial Contractile Function in Humans Circulation, June 15, 1999; 99(23): 3024 - 3027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nattel Atrial electrophysiological remodeling caused by rapid atrial activation: underlying mechanisms and clinical relevance to atrial fibrillation Cardiovasc Res, May 1, 1999; 42(2): 298 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J.J.M. Brundel, I. C. Van Gelder, R. H. Henning, A. E. Tuinenburg, L. E. Deelman, R. G. Tieleman, J. G. Grandjean, W. H. Van Gilst, and H. J.G.M. Crijns Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation Cardiovasc Res, May 1, 1999; 42(2): 443 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sparks, S. Jayaprakash, H. G. Mond, J. K. Vohra, L. E. Grigg, and J. M. Kalman Left atrial mechanical function after brief duration atrial fibrillation J. Am. Coll. Cardiol., February 1, 1999; 33(2): 342 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.J. Meurling, M.P. Ingemansson, A. Roijer, J. Carlson, C.J. Lindholm, B. Smideberg, L. Sorno, M. Stridh, and S.B. Olsson Attenuation of electrical remodelling in chronic atrial fibrillation following oral treatment with verapamil Europace, January 1, 1999; 1(4): 234 - 241. [Abstract] [PDF]
|
|
|
|
|
|
E. K. Louie, D. Liu, S. I. Reynertson, H. S. Loeb, T. L. McKiernan, P. J. Scanlon, and R. J. Hariman "Stunning" of the left atrium after spontaneous conversion of atrial fibrillation to sinus rhythm: Demonstration by transesophageal Doppler techniques in a canine model J. Am. Coll. Cardiol., December 1, 1998; 32(7): 2081 - 2086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sun, R. Gaspo, N. Leblanc, and S. Nattel Cellular Mechanisms of Atrial Contractile Dysfunction Caused by Sustained Atrial Tachycardia Circulation, August 18, 1998; 98(7): 719 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Hoit, Y. Shao, and M. Gabel Left atrial systolic and diastolic function accompanying chronic rapid pacing-induced atrial failure Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H183 - H189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Yu, S.-A. Chen, S.-H. Lee, C.-T. Tai, A.-N. Feng, B. I.-T. Kuo, Y.-A. Ding, and M.-S. Chang Tachycardia-Induced Change of Atrial Refractory Period in Humans : Rate Dependency and Effects of Antiarrhythmic Drugs Circulation, June 16, 1998; 97(23): 2331 - 2337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Van Wagoner, A. L. Pond, P. M. McCarthy, J. S. Trimmer, and J. M. Nerbonne Outward K+ Current Densities and Kv1.5 Expression Are Reduced in Chronic Human Atrial Fibrillation Circ. Res., June 19, 1997; 80(6): 772 - 781. [Abstract] [Full Text]
|
|
|
|
|
|
R. G. Tieleman, C. D. J. De Langen, I. C. Van Gelder, P. J. de Kam, J. Grandjean, K. J. Bel, M. C. E. F. Wijffels, M. A. Allessie, and H. J. G. M. Crijns Verapamil Reduces Tachycardia-Induced Electrical Remodeling of the Atria Circulation, April 1, 1997; 95(7): 1945 - 1953. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||